|
[1]WHO.Obesity and overweight:fact sheet[C/OL].2016.http:/www.who.int/mediacentre/factsheets/fs311/en/.
|
|
[2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.
|
|
[3]DYSON J, JAQUES B, CHATTOPADYHAY D, et al.Hepatocellular cancer:the impact of obesity, type 2 diabetes and a multidisciplinary team[J].J Hepatol, 2014, 60 (1) :110-117.
|
|
[4]WONG RJ, AGUILAR M, CHEUNG R, et al.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States[J].Gastroenterology, 2015, 148 (3) :547-555.
|
|
[5]KABBANY MN, CONJEEVARAM SELVAKUMAR PK, WATT K, et al.Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States:an analysis of national health and nutrition examination survey data[J].Am J Gastroenterol, 2017, 112 (4) :581-587.
|
|
[6]ESTES C, RAZAVI H, LOOMBA R, et al.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J].Hepatology, 2017.[Epub ahead of print]
|
|
[7]HAAS JT, FRANCQUE S, STAELS B.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J].Annu Rev Physiol, 2016, 78:181-205.
|
|
[8]ADAMS LA, ANSTEE QM, TILG H, et al.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J].Gut, 2017, 66 (6) :1138-1153.
|
|
[9]SANYAL AJ, FRIEDMAN SL, MCCULLOUGH AJ, et al.Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:findings and recommendations from an American Association for the Study of Liver Diseases-U.S.Food and Drug Administration Joint Workshop[J].Hepatology, 2015, 61 (4) :1392-1405.
|
|
[10] European Association for the Study of the Liver.EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol, 2016, 64 (6) :1388-1402.
|
|
[11] CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology, 2017.[Epub ahead of print]
|
|
[12]LOOMBA R, SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :686-690.
|
|
[13]KLEINER DE, BRUNT EM, van NATTA M, et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J].Hepatology, 2005, 41 (6) :1313-1321.
|
|
[14]WILLIAMS CD, STENGEL J, ASIKE MI, et al.Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy:a prospective study[J].Gastroenterology, 2011, 140 (1) :124-131.
|
|
[15]ADAMS LA, LYMP JF, ST SAUVER J, et al.The natural history of nonalcoholic fatty liver disease:a population-based cohort study[J].Gastroenterology, 2005, 129 (1) :113-121.
|
|
[16]KLEINER D, BRUNT EM, BELT P, et al.Diagnostic pattern and disease activity are related to disease progression and regression in nonalcoholic fatty liver disease[J].Hepatology, 2016, 64 (S1) .
|
|
[17]MCPHERSON S, HARDY T, HENDERSON E, et al.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:implications for prognosis and clinical management[J].J Hepatol, 2015, 62 (5) :1148-1155.
|
|
[18]EKSTEDT M, HAGSTROM H, NASR P, et al.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up[J].Hepatology, 2015, 61 (5) :1547-1554.
|
|
[19]SINGH S, ALLEN AM, WANG Z, et al.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies[J].Clin Gastroenterol Hepatol, 2015, 13 (4) :643-54.
|
|
[20]WONG VW, WONG GL, CHOI PC, et al.Disease progression of non-alcoholic fatty liver disease:a prospective study with paired liver biopsies at 3 years[J].Gut, 2010, 59 (7) :969-974.
|
|
[21]SANYAL AJ, BANAS C, SARGEANT C, et al.Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C[J].Hepatology, 2006, 43 (4) :682-689.
|
|
[22]BHALA N, ANGULO P, van DER POORTEN D, et al.The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis:an international collaborative study[J].Hepatology, 2011, 54 (4) :1208-1216.
|
|
[23]KAWAMURA Y, ARASE Y, IKEDA K, et al.Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma[J].Am J Gastroenterol, 2012, 107 (2) :253-261.
|
|
[24]ASCHA MS, HANOUNEH IA, LOPEZ R, et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].Hepatology, 2010, 51 (6) :1972-1978.
|
|
[25]YATSUJI S, HASHIMOTO E, TOBARI M, et al.Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C[J].J Gastroenterol Hepatol, 2009, 24 (2) :248-254.
|
|
[26]MOHAMAD B, SHAH V, ONYSHCHENKO M, et al.Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis[J].Hepatol Int, 2016, 10 (4) :632-639.
|
|
[27]ANGULO P, KLEINER DE, DAM-LARSEN S, et al.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J].Gastroenterology, 2015, 149 (2) :389-397, e10.
|
|
[28]HAGSTROM H, NASR P, EKSTEDT M, et al.Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD[J].J Hepatol, 2017.[Epub ahead of print]
|
|
[29] DULAI PS, SINGH S, PATEL J, et al.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis[J].Hepatology, 2017, 65 (5) :1557-1565.
|
|
[30]ADAMS LA, SANDERSON S, LINDOR KD, et al.The histological course of nonalcoholic fatty liver disease:a longitudinal study of103 patients with sequential liver biopsies[J].J Hepatol, 2005, 42 (1) :132-138.
|
|
[31]PAIS R, CHARLOTTE F, FEDCHUK L, et al.A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver[J].J Hepatol, 2013, 59 (3) :550-556.
|
|
[32]SHIGEFUKU R, TAKAHASHI H, NAKANO H, et al.Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease:comparison with chronic hepatitis related to hepatitis C virus[J].Int J Mol Sci, 2016, 17 (9) :1545.
|
|
[33]STINE JG, SHAH NL, ARGO CK, et al.Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis[J].Liver Transpl, 2015, 21 (8) :1016-1021.
|
|
[34]KIM D, KIM WR, KIM HJ, et al.Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States[J].Hepatology, 2013, 57 (4) :1357-1365.
|
|
[35]BRIL F, BARB D, PORTILLO-SANCHEZ P, et al.Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease[J].Hepatology, 2017, 65 (4) :1132-1144.
|
|
[36]European Association for Study of Liver;Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.
|
|
[37]CASSINOTTO C, BOURSIER J, de LEDINGHEN V, et al.Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging, Fibro Scan, and ARFI with liver biopsy[J].Hepatology, 2016, 63 (6) :1817-1827.
|
|
[38]PETTA S, MAIDA M, MACALUSO FS, et al.The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease[J].Hepatology, 2015, 62 (4) :1101-1110.
|
|
[39]JOO SK, KIM W, KIM D, et al.Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease[J].Liver Int, 2017.[Epub ahead of print]
|
|
[40]BRUNT EM.Nonalcoholic fatty liver disease:pros and cons of histologic systems of evaluation[J].Int J Mol Sci, 2016, 17 (1) .Pii:E97.
|
|
[41]BRAVO AA, SHETH SG, CHOPRA S.Liver biopsy[J].N Engl JMed, 2001, 344 (7) :495-500.
|
|
[42]RATZIU V, CHARLOTTE F, HEURTIER A, et al.Sampling variability of liver biopsy in nonalcoholic fatty liver disease[J].Gastroenterology, 2005, 128 (7) :1898-906.
|
|
[43]GOLDSTEIN NS, HASTAH F, GALAN MV, et al.Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens[J].Am J Clin Pathol, 2005, 123 (3) :382-387.
|
|
[44]SAAB S, PHAN J, JIMENEZ MA, et al.Endoscopic ultrasound liver biopsies accurately predict the presence of fibrosis in patients with fatty liver[J].Clin Gastroenterol Hepatol, 2017, 15 (9) :1477-1478.
|
|
[45]BEDOSSA P, CONSORTIUM FP.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology, 2014, 60 (2) :565-575.
|
|
[46]BRUNT EM, JANNEY CG, di BISCEGLIE AM, et al.Nonalcoholic steatohepatitis:a proposal for grading and staging the histological lesions[J].Am J Gastroenterol, 1999, 94 (9) :2467-2474.
|
|
[47]MATTEONI CA, YOUNOSSI ZM, GRAMLICH T, et al.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity[J].Gastroenterology, 1999, 116 (6) :1413-1419.
|
|
[48]PAVLIDES M, BIRKS J, FRYER E, et al.Interobserver variability in histologic evaluation of liver fibrosis using categorical and quantitative scores[J].Am J Clin Pathol, 2017, 147 (4) :364-369.
|
|
[49]GERMANI G, HYTIROGLOU P, FOTIADU A, et al.Assessment of fibrosis and cirrhosis in liver biopsies:an update[J].Semin Liver Dis, 2011, 31 (1) :82-90.
|
|
[50]ZIOL M, KETTANEH A, GANNE-CARRIE N, et al.Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis[J].Eur J Gastroenterol Hepatol, 2009, 21 (11) :1261-1268.
|
|
[51]WANG Y, HOU JL.Fibrosis assessment:impact on current management of chronic liver disease and application of quantitative invasive tools[J].Hepatol Int, 2016, 10 (3) :448-461.
|
|
[52]ASSELAH T, MARCELLIN P, BEDOSSA P.Improving performance of liver biopsy in fibrosis assessment[J].J Hepatol, 2014, 61 (2) :193-195.
|
|
[53]PATEL K, BEDOSSA P, CASTERA L.Diagnosis of liver fibrosis:present and future[J].Semin Liver Dis, 2015, 35 (2) :166-183.
|
|
[54]BEDOSSA P, PATEL K.Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease[J].Gastroenterology, 2016, 150 (8) :1811-1822.
|
|
[55]SHIHA G, IBRAHIM A, HELMY A, et al.Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:a 2016update[J].Hepatol Int, 2017, 11 (1) :1-30.
|
|
[56]XU S, WANG Y, TAI DC, et al.q Fibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].JHepatol, 2014, 61 (2) :260-269.
|
|
[57]WANG Y, HUANG W, LI R, et al.Systematic quantitation of histologic patterns shows accuracy in reflecting cirrhotic remodeling[J].JGastroenterol Hepatol, 2017, 32 (9) :1631-1639.
|
|
[58]WANG Y, VINCENT R, YANG J, et al.Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis[J].Hepatology, 2017, 65 (6) :1891-1903.
|
DownLoad: